Phreesia, INC Form 4 insider transactions
NYSE
Balaji Gandhi, CFO of Phreesia, Inc., reports acquiring 12,865 shares of common stock on April 4, 2025, bringing his total holdings to 116,456 shares.
NYSE
Form 4: Phreesia Inc. Executive Allison C. Hoffman Reports Acquisition of 10,720 Shares of Common Stock
Allison C. Hoffman, General Counsel & Secretary of Phreesia Inc., reports acquiring 10,720 shares of common stock on April 4, 2025, through the conversion of a cash bonus into Restricted Stock Units (RSUs).
NYSE
Yvonne Hui, Principal Accounting Officer of Phreesia Inc., reports the acquisition of 4,680 Restricted Stock Units (RSUs) in lieu of a cash bonus, fully vested as of the grant date.
NYSE
Amy Beth VanDuyn, SVP of Human Resources at Phreesia, Inc., reports the acquisition of 3,752 Restricted Stock Units (RSUs) in lieu of a portion of her cash bonus.
NYSE
Phreesia's CEO, Chaim Indig, acquired shares in lieu of a cash bonus and corrected a previous overstatement of holdings.
NYSE
Form 4: Phreesia Inc. Executive Evan Roberts Reports Acquisition of Shares Via Restricted Stock Units
Evan Roberts, Chief Operating Officer of Phreesia Inc., reports acquiring 12,865 shares of common stock through Restricted Stock Units (RSUs) in lieu of a cash bonus.
NYSE
David Linetsky, SVP of Life Sciences at Phreesia, Inc., filed a Form 4 detailing a corrected stock holding and a grant of Restricted Stock Units (RSUs) in lieu of a portion of his cash bonus.
NYSE
Edward Cahill, a director at Phreesia, Inc., filed an amended Form 4 to correct the reported amount of securities beneficially owned, including previously omitted restricted stock units.
NYSE
Michael Weintraub, a director of Phreesia Inc., filed an amended Form 4 to correct an overstatement of direct share ownership in a previous filing.
NYSE
Balaji Gandhi, CFO of Phreesia, Inc., sold 1,827 shares of common stock on March 26, 2025, to cover tax withholding obligations related to the settlement of restricted stock units.
NYSE
David Linetsky, SVP of Life Sciences at Phreesia, Inc., reported the sale of common stock to cover tax withholding obligations related to the settlement of restricted stock units.
NYSE
Allison C. Hoffman, General Counsel & Secretary of Phreesia, Inc., sold 3,496 shares of common stock at $25.32 per share on March 17, 2025, under a pre-arranged trading plan.
NYSE
Evan Roberts, Chief Operating Officer of Phreesia, Inc., sold shares of common stock on February 18 and 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Balaji Gandhi, CFO of Phreesia, Inc., sold shares of common stock on February 18 and 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Allison Hoffman, General Counsel & Secretary of Phreesia Inc., sold 3,496 shares of common stock at $29.72 per share on February 18, 2025, under a pre-arranged 10b5-1 trading plan.
NYSE
Phreesia's Chief Operating Officer, Evan Roberts, executed sales of common stock on February 13 and 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Balaji Gandhi, CFO of Phreesia, Inc., sold a portion of his common stock holdings on February 13 and 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 11,616 shares of common stock at an average price of $29.7005 per share under a pre-arranged 10b5-1 trading plan.
NYSE
David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 300 shares of common stock at an average price of $29.5233 under a pre-arranged 10b5-1 trading plan.
NYSE
David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 720 shares of common stock at an average price of $29.5013 per share on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Director Gillian Munson acquired 351 shares of Phreesia Inc. common stock at $28.46 per share on January 31, 2025, through deferred stock units.
NYSE
A Phreesia director has elected to receive deferred stock units instead of a cash retainer, according to a recent SEC filing.
NYSE
Director Edward Cahill acquired 351 shares of Phreesia, Inc. common stock through deferred stock units, increasing his total holdings to 47,383 shares.
NYSE
David Linetsky, SVP of Life Sciences at Phreesia, sold 500 shares of common stock at an average price of $29.682, as part of a pre-arranged trading plan.
NYSE
Balaji Gandhi, CFO of Phreesia, Inc., sold shares of common stock on January 27, 2025, to cover tax withholding obligations related to the settlement of performance-based restricted stock units.
NYSE
Allison Hoffman, General Counsel & Secretary of Phreesia Inc., sold shares of common stock on January 27 and 28, 2025, to cover tax withholding obligations and pursuant to a pre-arranged trading plan.
NYSE
David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold shares of common stock to cover tax withholding obligations related to the settlement of performance-based restricted stock units.
NYSE
Phreesia Inc.'s Chief Operating Officer, Evan Roberts, disposed of shares to cover tax withholding obligations related to the settlement of performance-based restricted stock units.
NYSE
Phreesia's CEO, Chaim Indig, disposed of shares to cover tax withholding obligations related to the settlement of performance-based restricted stock units.
NYSE
Amy Beth VanDuyn, SVP of Human Resources at Phreesia Inc., sold shares of common stock to cover tax withholding obligations related to the settlement of performance-based restricted stock units.